Scarica l'app Stockscreener
42.11
5.17%
2.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$40.04
Aprire:
$39.66
Volume 24 ore:
2.83M
Relative Volume:
0.93
Capitalizzazione di mercato:
$6.46B
Reddito:
-
Utile/perdita netta:
$-284.08M
Rapporto P/E:
-17.38
EPS:
-2.4234
Flusso di cassa netto:
$-234.65M
1 W Prestazione:
+8.61%
1M Prestazione:
+19.43%
6M Prestazione:
+483.24%
1 anno Prestazione:
+404.92%
Intervallo 1D:
$39.26
$42.24
Intervallo di 1 settimana:
$37.86
$43.73
Portata 52W:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Confronta COGT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
42.11 | 6.15B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-10 | Aggiornamento | Stifel | Hold → Buy |
| 2025-11-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-10-16 | Iniziato | Stifel | Hold |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Birchview Capital LP Buys New Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
COGT Boom: Is It Time to Cash In? - StocksToTrade
Redmile Group LLC Sells 1,767,986 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Will Rising Interest Rates Hurt Piramal Pharma Limiteds Profit MarginsHead and Shoulders Patterns & Access Free Tools and Start Investing - earlytimes.in
Cogent Biosciences (COGT): Valuation Check After Positive APEX Part 2 Trial Results for Bezuclastinib - Sahm
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - Investing News Network
Cogent Biosciences Presents Positive Clinical Trial Results - TradingView
Cogent Biosciences (NASDAQ:COGT) Given "Hold" Rating at Needham & Company LLC - MarketBeat
Cogent Biosciences (COGT) Receives 'Hold' Rating from Needham | - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Reaches New 1-Year HighHere's What Happened - MarketBeat
Wedbush Adjusts Cogent Biosciences Price Target to $55 From $38, Maintains Outperform Rating - marketscreener.com
Cogent Biosciences Says Bezuclastinib Showed 'Rapid and Deep Clinical Benefit' in Advanced Systemic Mastocytosis Trial - marketscreener.com
Cogent Biosciences stock hits all-time high at 43.07 USD By Investing.com - Investing.com Nigeria
Cogent Biosciences stock hits all-time high at 43.07 USD - Investing.com
Cogent Biosciences : COGT ASH 2025 Webcast FINAL - marketscreener.com
Cogent Biosciences (COGT) Reports Positive Results from APEX Par - GuruFocus
Cogent Biosciences announces positive top-line results of apex trial of bezuclastinib in patients with advanced systemic mastocytosis - marketscreener.com
Cogent Biosciences Announces Positive Top-Line Results Of APEX Trial Of Bezuclastinib In Patients With Advanced Systemic Mastocytosis - TradingView
Cogent Biosciences, Inc. Announces Positive Top-Line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - marketscreener.com
Schroder Investment Management Group Invests $896,000 in Cogent Biosciences, Inc. $COGT - MarketBeat
Bollard Group LLC Buys New Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences' (COGT) Bezuclastinib Shows Promising Results in Clinical Trial - GuruFocus
Cogent Biosciences, Inc. $COGT Shares Purchased by Kennedy Capital Management LLC - MarketBeat
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis at the 67th Annual Meeting of the American Society of Hematology - Investing News Network
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) - The Manila Times
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) - GlobeNewswire Inc.
Tema Etfs LLC Has $845,000 Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cogent Biosciences prices equity offering and 1.625% convertible senior notes - MSN
Cogent Biosciences, Inc. $COGT is Saturn V Capital Management LP's 5th Largest Position - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cogent Biosciences Earnings Notes - Trefis
Is Cogent Biosciences Inc a good long term investmentREITs Market Trends & Free Exceptional ROI Methods - earlytimes.in
Can Cogent Biosciences Inc. stock deliver consistent earnings growthJuly 2025 Technicals & High Conviction Buy Zone Alerts - Newser
Stock Traders Buy Large Volume of Cogent Biosciences Call Options (NASDAQ:COGT) - MarketBeat
XTX Topco Ltd Has $836,000 Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Stock Analysis Report | Financials & Insights - Benzinga
Virtus Investment Advisers LLC Has $94,000 Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Price Target Increased by 93.94% to 43.52 - MSN
Geode Capital Management LLC Raises Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
F m Investments LLC Takes Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Ensign Peak Advisors Inc Grows Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences stock hits 52-week high at 40.76 USD By Investing.com - Investing.com Nigeria
Cogent Biosciences stock hits 52-week high at 40.76 USD - Investing.com
A Look at Cogent Biosciences (COGT) Valuation Following Positive Phase 3 Trial Results - Sahm
Cogent Biosciences (NASDAQ:COGT) Reaches New 52-Week HighWhat's Next? - MarketBeat
Biotech Star Cogent Rides High On Breakthrough Trial Hopes - Finimize
Cogent Biosciences Announces $230 Million Convertible Senior Notes Offering - Global Legal Chronicle
Cogent Biosciences (COGT): Evaluating Valuation After Positive Phase 3 Cancer Trial Results and New Drug Plans - Yahoo Finance
Cogent Biosciences Completes $345 Million Common Stock Offering and $200 Million Convertible Notes Offering - Global Legal Chronicle
Top Biotech Stocks To ConsiderNovember 20th - MarketBeat
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):